representative approved innovations reviewed
China-developed products spanning CAR-T, bispecific antibodies, antibody-drug conjugates and precision targeted therapies.
Start a free inquiry China Healthcare Insights · Evidence Map
China Oncology Innovation Evidence
China's oncology ecosystem now combines commercially available therapies, a fast-moving clinical pipeline, growing global pharmaceutical partnerships and emerging evidence of international patient access.
This page separates treatments approved for defined indications, investigational therapies available only through clinical studies, and preclinical programs that have not yet entered human testing. It also documents selected international licensing transactions and independently reported patient journeys.
Last reviewed: 23 September 2026
Direct answer
What evidence shows that China is becoming an oncology innovation centre?
The evidence includes China-developed cancer therapies approved by Chinese and overseas regulators, global licensing and acquisition by international pharmaceutical companies, a growing clinical pipeline, and independently reported international patients receiving approved treatment in China. These evidence types are not equivalent: approved therapy, clinical research, preclinical science and commercial licensing must be evaluated separately.
representative global transactions reviewed
International pharmaceutical companies have licensed or acquired China-origin oncology assets.
development stages separated
Commercial, clinical and preclinical status is shown independently from deal value or scientific interest.
named public patient journeys
Independent media reports—not MedVoyage China testimonials.
Approved oncology innovations
Representative therapies with defined approved indications
The following therapies are approved only for the stated indications. Some approvals are conditional or accelerated. Treatment decisions require specialist review of diagnosis, pathology, biomarkers, prior therapy, organ function and current disease status.
Satricabtagene autoleucel (satri-cel / CT041)
CARsgen Therapeutics
- Modality / focus
- Claudin18.2 CAR-T
- Indication or evidence stage
- China: Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma after failure of at least two prior lines.
- Patient access
- Approved and commercially available in China. NMPA approval announced 22 Jun 2026. Eligibility remains highly specific.
- Why it matters
- Reported as the world's first approved CAR-T product for a solid tumour.
Ivonescimab
Akeso
- Modality / focus
- PD-1 × VEGF bispecific antibody
- Indication or evidence stage
- China: approved indications include EGFR-mutated non-squamous NSCLC after EGFR-TKI progression and first-line PD-L1-positive advanced NSCLC.
- Patient access
- Approved and commercially available in China. Use must follow the exact approved indication and regimen.
- Why it matters
- A China-origin bispecific antibody that advanced through head-to-head Phase III development and international licensing.
Cadonilimab
Akeso
- Modality / focus
- PD-1 × CTLA-4 bispecific antibody
- Indication or evidence stage
- China: recurrent or metastatic cervical cancer after platinum-based chemotherapy; first-line locally advanced unresectable or metastatic gastric/GEJ cancer in an approved combination.
- Patient access
- Approved and commercially available in China. Indication-specific use only.
- Why it matters
- Described by the developer as the first approved dual immune-checkpoint bispecific antibody.
Disitamab vedotin (RC48)
RemeGen
- Modality / focus
- HER2-directed ADC
- Indication or evidence stage
- China: conditionally approved indications include HER2-expressing advanced gastric/GEJ adenocarcinoma and locally advanced or metastatic urothelial carcinoma in defined previously treated populations.
- Patient access
- Approved and commercially available in China. Conditional approval and biomarker requirements apply.
- Why it matters
- The first original China-developed ADC to receive marketing approval, according to the developer.
RemeGen approval announcement ↗ · Urothelial evidence and approval context ↗
Sunvozertinib (Zegfrovy)
Dizal Pharma
- Modality / focus
- Oral EGFR tyrosine-kinase inhibitor
- Indication or evidence stage
- China and US: previously treated locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, subject to the relevant local label.
- Patient access
- Approved and commercially available in the approved markets. China approval 2023; US accelerated approval 2025.
- Why it matters
- A China-origin precision therapy subsequently approved by the US FDA.
Fruquintinib (Elunate / Fruzaqla)
HUTCHMED; global partner Takeda
- Modality / focus
- Oral VEGFR-1/2/3 inhibitor
- Indication or evidence stage
- Previously treated metastatic colorectal cancer; labels vary by market.
- Patient access
- Approved and commercially available in China, the US, EU and other markets. China approval 2018; US approval 2023; EU approval 2024.
- Why it matters
- A China-discovered oncology medicine that achieved approvals across major international markets.
Savolitinib (Orpathys)
HUTCHMED; partnered with AstraZeneca
- Modality / focus
- Oral MET inhibitor
- Indication or evidence stage
- China: locally advanced or metastatic NSCLC with MET exon 14 skipping alterations under the conditions specified in the label.
- Patient access
- Approved and commercially available in China. Initially granted conditional approval in 2021.
- Why it matters
- A precision therapy developed through a China–global pharmaceutical collaboration.
Equecabtagene autoleucel (Fucaso)
IASO Bio / Innovent
- Modality / focus
- BCMA CAR-T
- Indication or evidence stage
- China: adults with relapsed or refractory multiple myeloma after at least three prior lines including a proteasome inhibitor and immunomodulatory drug.
- Patient access
- Approved and commercially available in China. NMPA approval 30 Jun 2023.
- Why it matters
- A domestically developed BCMA-directed CAR-T option for heavily pretreated multiple myeloma.
Zevorcabtagene autoleucel (zevor-cel)
CARsgen Therapeutics
- Modality / focus
- BCMA CAR-T
- Indication or evidence stage
- China: adults with relapsed or refractory multiple myeloma after progression following at least three prior lines, as specified in the label.
- Patient access
- Approved and commercially available in China. NMPA approval 23 Feb 2024.
- Why it matters
- Adds another China-developed cellular-therapy option in multiple myeloma.
Approval does not establish eligibility for an individual case.
Request an Oncology Case Review →Clinical and preclinical pipeline
Development stage matters.
Clinical activity does not equal regulatory approval, and preclinical research is not a patient treatment option.
SSGJ-707 / PF'4404
3SBio; licensed to Pfizer outside China
- Modality / focus
- PD-1 × VEGF bispecific antibody; multiple solid tumours
- Indication or evidence stage
- Multiple clinical trials were underway in China when licensed; global development is continuing. Not approved for general commercial use.
- Patient access
- Clinical-trial access only; current recruitment and eligibility require direct registry and site confirmation.
BNT327 / PM8002
Biotheus; acquired by BioNTech
- Modality / focus
- PD-L1 × VEGF-A bispecific antibody; multiple solid tumours
- Indication or evidence stage
- Described as a late-stage clinical asset; programs include Phase 2/3 development. Not approved for general commercial use.
- Patient access
- Clinical-trial access only.
HS-20093 / GSK5764227
Hansoh Pharma; licensed to GSK outside Greater China
- Modality / focus
- B7-H3-targeted ADC; lung cancer and other solid tumours
- Indication or evidence stage
- Phase I–III programs have been reported in China; global development is underway. Not approved for general commercial use.
- Patient access
- Clinical-trial access only.
Sacituzumab tirumotecan (sac-TMT / SKB264 / MK-2870)
Kelun-Biotech; licensed to Merck outside Greater China
- Modality / focus
- TROP2-directed ADC; multiple solid tumours
- Indication or evidence stage
- Global Phase III development has been reported. Not approved for general commercial use as of this review.
- Patient access
- Clinical-trial access only.
Selected option ADCs in the 2022 Kelun–Merck portfolio agreement
Kelun-Biotech / Merck
- Modality / focus
- Seven investigational ADC candidates
- Indication or evidence stage
- Preclinical / Discovery at signing. Individual assets may subsequently advance, so each must be checked separately before a current-stage claim is made.
- Patient access
- No patient access may be inferred from the portfolio agreement.
Development stages can change quickly. “Clinical trial” does not mean that a study is recruiting, open to international patients or appropriate for a particular case. Trial participation requires protocol-specific screening and informed consent.
Global pharmaceutical partnerships
Commercial validation, shown separately from medical status.
International licensing and acquisition can provide evidence of scientific and commercial validation. It does not, by itself, establish safety, efficacy, regulatory approval or patient availability.
SSGJ-707 / PF'4404
3SBio · Pfizer
- Transaction
- Exclusive global licence outside China, with an option involving China rights
- Terms disclosed at announcement
- US$1.25bn payment on completion; US$100m equity investment; additional option and milestone economics apply.
BNT327 / PM8002 and Biotheus platform
Biotheus · BioNTech
- Transaction
- Acquisition of Biotheus; completed Feb 2025
- Terms disclosed at announcement
- US$800m upfront consideration, plus up to US$150m in performance-based payments.
Seven investigational ADC candidates
Kelun-Biotech · Merck
- Transaction
- Exclusive licence and collaboration covering a portfolio of ADC candidates
- Terms disclosed at announcement
- US$175m upfront; up to US$9.3bn in development, regulatory and sales milestones if specified conditions are met, plus royalties.
HS-20093 / GSK5764227
Hansoh Pharma · GSK
- Transaction
- Exclusive worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan
- Terms disclosed at announcement
- US$185m upfront; up to US$1.525bn in success-based milestones, plus tiered royalties.
HS-20089
Hansoh Pharma · GSK
- Transaction
- Exclusive worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan
- Terms disclosed at announcement
- US$85m upfront; up to US$1.485bn in success-based milestones, plus tiered royalties.
Ivonescimab ex-China rights
Akeso · Summit Therapeutics
- Transaction
- Licence to develop and commercialise ivonescimab in specified territories outside Greater China
- Terms disclosed at announcement
- US$500m upfront; original total potential deal value up to US$5bn including regulatory and commercial milestones, plus royalties.
Publicly Reported Patient Cases
International Patients Seeking Oncology Care in China
The following patient journeys were reported by independent media. They are not MedVoyage China patient testimonials, and MedVoyage China was not involved in the care described below. Reported outcomes represent a specific point in time and cannot predict another patient's result.
Michael Walters, age 25, New Zealand
- Diagnosis reported
- Non-Hodgkin lymphoma
- Treatment setting
- SinoUnited Hospital, Shanghai
- Treatment type
- CAR-T for a blood cancer after previous chemotherapy, radiotherapy and immunotherapy had not achieved the needed result.
- Reported outcome
- The Wall Street Journal reported that Walters was told on 18 August 2026 that the treatment had produced complete remission. This is a media-reported snapshot, not a guarantee of durability.
- Why China was considered
- Reported factors included treatment access, cost, specialist experience, English-language communication and coordination support.
Josh Bronkhorst, age 59, New Zealand
- Diagnosis reported
- Advanced gastric cancer
- Treatment setting
- Jiahui International Hospital, Shanghai
- Treatment type
- Satri-cel following its 2026 Chinese approval for a defined Claudin18.2-positive, HER2-negative later-line gastric/GEJ cancer population.
- Reported outcome
- The Wall Street Journal reported early post-infusion improvement in fluid accumulation and that the patient returned to New Zealand to continue recovery. The report did not establish a durable long-term response at publication.
- Why China was considered
- The patient reportedly pursued the option after prior therapy and an unfavorable assessment of another chemotherapy course.
These cases document international patient access; they do not advertise a guaranteed outcome. No patient should travel or change treatment on the basis of a media report. Independent oncology review and direct confirmation from the treating hospital are required.
Begin with complete records and qualified specialist evaluation.
Request an Oncology Case Review →Patient pathway
Could Any of These Treatment Pathways Be Relevant to Your Case?
The relevant question is not whether an innovative therapy exists. It is whether the therapy is approved or investigational, whether its indication matches the diagnosis, and whether the patient meets the hospital's clinical criteria.
- Organize pathology, imaging, treatment history and biomarker reports.
- Identify appropriate oncology specialists and hospitals in China.
- Distinguish approved treatment from clinical-trial options.
- Request an initial medical evaluation and preliminary eligibility review.
- Coordinate communication, translation and the next-stage care pathway.
Treatment eligibility depends on diagnosis, pathology, molecular biomarkers, previous treatment, disease status, organ function and hospital assessment. A licensing announcement, clinical-trial listing or public patient story does not establish individual eligibility.
Frequently asked questions
Questions to resolve before considering access.
Are China-developed cancer therapies available to international patients?
Some approved therapies may be available to eligible international patients through hospitals authorised and equipped to provide them. Availability must be confirmed directly because approval, hospital access, international-patient acceptance and individual eligibility are separate questions.
Does an international licensing deal mean that the therapy is approved?
No. A licensing or acquisition transaction can indicate scientific and commercial interest, but the asset may still be in preclinical research or clinical trials. Regulatory approval must be verified separately for each country and indication.
Can international patients join cancer clinical trials in China?
Potentially, but not every study recruits international patients. Participation depends on the protocol, recruitment status, site policy, biomarker criteria, prior treatment and informed-consent requirements. Trial access should never be assumed from a press release.
Is CAR-T approved for solid tumours in China?
China approved satri-cel in June 2026 for a narrowly defined population with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma after failure of at least two prior lines of therapy. This does not mean CAR-T is approved for solid tumours generally.
Can a public patient story predict my result?
No. A patient story describes one person's diagnosis, treatment history and outcome at a particular time. It cannot establish expected benefit or risk for another patient.
What records are needed for an initial oncology review?
Typically: pathology and immunohistochemistry reports, molecular or genomic results, recent imaging and reports, treatment history with dates and responses, current laboratory results, discharge summaries and a concise description of the patient's current condition.
Related MedVoyage pathways
Continue with evaluation and coordination.
Medical and editorial disclaimer
This page is for general informational and evidence-navigation purposes only. It does not provide medical advice, diagnosis or a treatment recommendation. Product approvals and clinical-trial statuses can change. Approved indications differ by country and may include conditions not fully reproduced in this summary. Patients should consult qualified oncology specialists and verify current regulatory, hospital and trial information before making any decision.
MedVoyage China is a cross-border healthcare service provider. It supports medical-record preparation, specialist matching and care coordination; it does not manufacture medicines, operate clinical trials or guarantee treatment eligibility or outcomes.
This is a selected evidence set, not a complete database of oncology products or clinical trials in China. Inclusion does not constitute a treatment recommendation, and regulatory approval does not establish eligibility for an individual patient.